OSE

OSE Immunotherapeutics (OSE)

OSE Immunotherapeutics

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:OSE

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/07/24	15:55	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis	EU:OSE	OSE Immunotherapeutics
2024/07/04	01:00	GlobeNewswire Inc.	Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371	EU:OSE	OSE Immunotherapeutics
2024/07/04	01:00	GlobeNewswire Inc.	Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371	EU:OSE	OSE Immunotherapeutics
2024/07/04	01:00	GlobeNewswire Inc.	OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer	EU:OSE	OSE Immunotherapeutics
2024/07/03	01:00	GlobeNewswire Inc.	Informations relatives au nombre total de droits de vote et d’actions composant le capital	EU:OSE	OSE Immunotherapeutics
2024/07/01	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/07/01	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’	EU:OSE	OSE Immunotherapeutics
2024/06/24	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies	EU:OSE	OSE Immunotherapeutics
2024/06/24	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies	EU:OSE	OSE Immunotherapeutics
2024/06/24	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T	EU:OSE	OSE Immunotherapeutics
2024/06/20	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)	EU:OSE	OSE Immunotherapeutics
2024/06/20	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)	EU:OSE	OSE Immunotherapeutics
2024/06/20	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)	EU:OSE	OSE Immunotherapeutics
2024/06/20	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société	EU:OSE	OSE Immunotherapeutics
2024/06/20	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth	EU:OSE	OSE Immunotherapeutics
2024/06/20	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth	EU:OSE	OSE Immunotherapeutics
2024/06/13	01:00	GlobeNewswire Inc.	OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse	EU:OSE	OSE Immunotherapeutics
2024/06/13	01:00	GlobeNewswire Inc.	OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse	EU:OSE	OSE Immunotherapeutics
2024/06/13	01:00	GlobeNewswire Inc.	Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules	EU:OSE	OSE Immunotherapeutics
2024/06/05	14:30	GlobeNewswire Inc.	OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale	EU:OSE	OSE Immunotherapeutics
2024/06/05	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	EU:OSE	OSE Immunotherapeutics
2024/06/05	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	EU:OSE	OSE Immunotherapeutics
2024/06/05	01:00	GlobeNewswire Inc.	Informations relatives au nombre total de droits de vote et d’actions composant le capital	EU:OSE	OSE Immunotherapeutics
2024/05/31	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics Provides Business and Corporate Update	EU:OSE	OSE Immunotherapeutics
2024/05/31	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics Provides Business and Corporate Update	EU:OSE	OSE Immunotherapeutics
2024/05/31	01:15	GlobeNewswire Inc.	OSE Immunotherapeutics fait le point sur ses avancées et sur la stratégie de croissance de la Société	EU:OSE	OSE Immunotherapeutics
2024/05/30	01:00	GlobeNewswire Inc.	Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024	EU:OSE	OSE Immunotherapeutics
2024/05/22	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases	EU:OSE	OSE Immunotherapeutics
2024/05/22	14:30	GlobeNewswire Inc.	OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases	EU:OSE	OSE Immunotherapeutics